Irritable Bowel Syndrome Treatment Companies
Certainly, here are descriptions of some notable companies that provide treatments or solutions for Irritable Bowel Syndrome (IBS)
Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Disclaimer: List of key companies in no particular orderLatest Irritable Bowel Syndrome Companies Update
-
October 2023: The U.S. subsidiary of Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals, and Sanofi announced a partnership to co-develop and co-commercialize asset TEV’574, which is presently undergoing Phase 2b clinical trials for the treatment of Crohn’s disease and ulcerative colitis, two forms of inflammatory bowel disease. Sanofi will spearhead the development of the Phase 3 program, and all companies will equally split the development expenses worldwide as well as net earnings and losses in important countries. Other markets will be subject to a royalty agreement. Teva will spearhead product commercialization in Europe, Israel, and a few other countries; Sanofi will handle North American, Japanese, other Asian, and global commercialization.
-
June 2023: The U.S. FDA authorized LINZESS® (linaclotide) as a once-daily therapy for children’s patients with functional constipation ages 6-17. This announcement was made by Ironwood Pharmaceuticals, Inc., a GI-focused healthcare firm. For this patient population, LINZESS is the first and only FDA-approved prescription medication for functional constipation. Our supplementary New Drug Application (sNDA) was given a 6-month priority review by the FDA early this year, which is four months ahead of the regular review schedule. In the US, AbbVie and Ironwood Pharmaceuticals are responsible for the development and marketing of LINZESS. Linacetide demonstrated a statistically significant and clinically relevant improvement in the primary endpoint of 12-week spontaneous bowel movement (SBM) frequency rate (SBMs/week) as compared to placebo in this crucial trial. Building on the class-leading formulary coverage currently in place for the brand, LINZESS 72mcg is now accessible for the treatment of functional constipation in pediatric patients aged 6 to 17 years old, based on FDA clearance.
List of Irritable Bowel Syndrome Key companies in the market
-
Valeant Pharmaceuticals International
-
Allergan Inc
-
Astellas Pharma
-
Lexicon Pharmaceuticals
-
Nestle Health Science
-
Synergy Pharmaceuticals Inc
-
Ironwood Pharmaceuticals
-
Ardelyx
-
Mallinckrodt
-
Abbott
Irritable Bowel Syndrome Treatment Market Highlights:
Irritable Bowel Syndrome Treatment Market Highlights:
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
